Amryt Announces Appointment of Dr. Tracy Cunningham as Chief Medical Officer
DUBLIN, Ireland, and Boston MA, June 27, 2022 Amryt (Nasdaq: AMYT), a commercial-stage global biopharmaceutical company focused on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Dr. Tracy Cunningham as Chief Medical Officer (CMO) effective immediately. Dr. Cunningham joined Amryt in April 2020 as Vice President, Chief Development Officer, Head of Preclinical and Clinical Development of the Amryt Portfolio. Previously, she held regional and global leadership positions at AstraZeneca, Novartis and GlaxoSmithKine. She is a graduate of the Royal College of Surgeons in Ireland and a Fellow of the Royal College of Physicians in Ireland.
Dr. Joe Wiley, CEO of Amryt Pharma, said: “I amvery happyto announce Tracy’s appointment as Chief Marketing Officer. Tracy has been an integral part of our team for2020as development managerandhas a strong track record of successful execution in this position. Tracytoobroughtawrich in experience ofotherthe rolesshe heldin hercareer before joining Amryt.”
Dr. Tracy Cunningham, CMO of Amryt Pharma, commented: “I amdelightedto assume my new roleas CMOand we look forward to continuing our workto bring new and innovative therapiesatimprove the lives of patients withrare sicknesss.”
Amryt is a commercial-stage global biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.
Amryt’s commercial activity includes three orphan disease products: metreleptin (Myalept®/ Myalepta®); oral octreotide (Mycapssa®); and lomitapide (Juxtapid®/Lojuxta®).
Myalept®/Myalepta® (metreleptin) is approved in the United States (under the trade name Myalept®) as an adjunct to diet as replacement therapy to treat complications of leptin deficiency in patients with generalized lipodystrophy ( GL) congenital or acquired and in the US (under the trade name Myalepta®) as an adjunct to diet for the treatment of leptin deficiency in patients with congenital or acquired GL in adults and children two years of age and older and familial or acquired partial lipodystrophy (PL) in adults and children 12 years and older for whom standard treatments have failed to achieve adequate metabolic control. For more information, please follow this link.
Mycapssa® (octreotide capsules) is approved in the United States for long-term maintenance therapy in patients with acromegaly who have responded to and tolerated treatment with octreotide or lanreotide. Mycapssa® is the first and only FDA-approved oral somatostatin analog. Mycapssa® has also been submitted to the EMA and is not yet approved in Europe. For more information, please follow this link.
Juxtapid®/Lojuxta® (lomitapide) is approved as an adjunct to a low-fat diet and other lipid-lowering medications for adults with the rare cholesterol disorder, homozygous familial hypercholesterolemia (“HoFH”) in the United States , in Canada, Colombia, Argentina and Japan (under the trade name Juxtapid®) and in the EU, Israel, Saudi Arabia and Brazil (under the trade name Lojuxta®). For more information, please follow this link.
Amryt’s lead development candidate, Oleogel-S10, is a potential treatment for the cutaneous manifestations of junctional and dystrophic epidermolysis bullosa (EB), a rare and distressing genetic skin condition affecting young children and adults. Filsuvez® was chosen as the brand name for Oleogel-S10. Filsuvez® has been CE approved in the EU for the treatment of partial thickness wounds associated with dystrophic and junctional EB in patients 6 months of age and older.
Amryt’s preclinical gene therapy candidate, AP103, offers a potential treatment for patients with dystrophic EB, and the polymer-based delivery platform has the potential to be developed for the treatment of other genetic disorders.
Amryt also intends to develop oral drugs that are currently only available as injectable therapies through its Transient Permeability Enhancer (TPE®) technology platform. For more information about Amryt, including products, please visit www.amrytpharma.com.
This announcement may contain forward-looking statements and the words “expect”, “anticipate”, “intend”, “plan”, “estimate”, “aim”, “expect”, “project” and similar expressions (or their negative) identify some of these forward-looking statements. The forward-looking statements contained in this announcement are based on numerous assumptions and on Amryt’s present and future business strategies and the environment in which Amryt expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause actual results, performance or achievements are materially different from those expressed or expressed. implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and make investments. Many of these risks and uncertainties relate to factors that are beyond Amryt’s ability to control or accurately estimate, such as future market conditions, developments in the COVID-19 pandemic, fluctuations currencies, the behavior of other market participants, the results of clinical trials, the actions of regulators and other factors such as Amryt’s ability to obtain financing, changes in the political, social and regulatory framework in which Amryt operates in either economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representations or warranties, express or implied, are made regarding future performance. No one is under any obligation to update or keep current the information contained in this announcement or to provide the recipient with access to any additional relevant information that may arise in connection with it. These forward-looking statements reflect the Company’s current beliefs and assumptions and are based on information currently available to management.
Copyright 2022 GlobeNewswire, Inc.